slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 66,121-66,150
Pages 3,679
Rows per page 30
Component
66,121-66,150 of 110,355
18
The slide explains the methodology behind the dataset used for AI lead optimization, specifically focusing on the combinatorial space of amino acid mutations.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
21
The slide highlights the methodology of sampling sequence space and validating predictive models against measured binding affinity.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
24
The slide uses a combination of diagrams and a summary box to explain the methodology of using AI to predict antibody naturalness.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
26
The slide uses box plots and density plots to demonstrate that higher naturalness correlates with better expression and lower mutational burden.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
27
The charts show the progression of antibody variants over generations, highlighting the improvement in ACE score and naturalness metrics.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
05
The slide uses a Gantt-style bar chart to represent clinical trial phases for each drug program.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
07
The slide uses a hierarchical diagram to map the clinical manifestations of the disease.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
08
The diagram illustrates the metabolic pathway and the specific block at the Cystathionine beta-synthase step.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
09
The table contrasts clinical outcomes (Hcy levels, lens dislocation, IQ, thrombosis, mortality) between two patient cohorts.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
10
Includes a citation of the specific clinical guidelines paper.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
11
Includes historical context of diagnostic methods (pre-NBS era).Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
14
The slide displays various medical nutrition products used for HCU management.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
15
Includes a clinical photograph of two patients, likely illustrating physical manifestations or growth issues associated with the condition.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
16
Case study format used to illustrate the consequences of poor disease management.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
17
The slide uses a list-based approach to describe the disease burden, paired with a visual column of key clinical manifestations.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
18
The slide uses a simple problem-solution structure, identifying the clinical gap and the resulting need.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
21
The slide uses a pie chart to show patient segmentation by B6 responsiveness and a timeline/number-line to show age of diagnosis, followed by key metrics on complication rates.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
23
The slide uses a process flow diagram to show the metabolic block (CBS deficiency) and the therapeutic intervention point.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
24
The slide uses a biological process diagram to contrast normal intracellular metabolism with the therapeutic effect of the drug in the plasma.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
25
The slide uses a process flow diagram to represent clinical trial cohorts and study design.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
09
Clinical trial data showing efficacy of Odevixibat (Bylvay) vs Placebo.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
10
The chart displays LS Mean (95% CI) with p-value significance markers.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
11
The chart shows statistically significant improvements (p<=0.01) for the treatment group across all time points after baseline.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
13
The slide highlights safety data for Odevixibat (Bylvay) over 24 weeks.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · Solution1 hit
03
Aldeyra Therapeutics | Results Presentation Deck | 13 slidesAldeyra Therapeutics | Results Presentation Deck | 13 slides · Aldeyra Therapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
04
Includes a faint background image of a vial and syringe.Aldeyra Therapeutics | Results Presentation Deck | 13 slides · Aldeyra Therapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
05
Aldeyra Therapeutics | Results Presentation Deck | 13 slidesAldeyra Therapeutics | Results Presentation Deck | 13 slides · Aldeyra Therapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
The slide uses a combination of a bar chart for preclinical data and a swimmer plot (timeline) for clinical patient outcomes.Aldeyra Therapeutics | Results Presentation Deck | 13 slides · Aldeyra Therapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
08
The slide outlines a clinical trial protocol with two study arms (ADX-2191 vs. routine care) over a 6-month period.Aldeyra Therapeutics | Results Presentation Deck | 13 slides · Aldeyra Therapeutics
Conference presentation Investor relations 1 hit
09
Clinical trial data presentation comparing a treatment group to a historical control group.Aldeyra Therapeutics | Results Presentation Deck | 13 slides · Aldeyra Therapeutics
Conference presentation Investor relations 1 hit